Citadel Advisors
CNST

Citadel Advisors’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

Citadel Advisors’s Portfolio CNST Stock Details CNST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-47,000
Closed -$1.1M – 14891
2021
Q1 		$1.1M Buy
47,000
+36,000
+327% +$1.09M ﹤0.01% 7883
2020
Q4 		$317K Buy
+11,000
New +$277K ﹤0.01% 8977
2020
Q2 		– Sell
-8,400
Closed -$264K – 10806
2020
Q1 		$264K Sell
8,400
-3,300
-28% -$115K ﹤0.01% 7547
2019
Q4 		$551K Buy
+11,700
New +$338K ﹤0.01% 6661

Other funds holding CNST

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
OPU
Omni Partners US Irvine, California $1.95B AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors's CNST Position: Q2 2021 in Review

Citadel Advisors sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q2 2021, closing a stake of 152,848 shares — an estimated $3.58M sold.

Citadel Advisors first reported a position in CNST in Q4 2019 and held it in 6 quarters. The position peaked at $9.48M in Q4 2020. 153 funds tracked by Wall St. Rank hold CNST as of Q2 2021.

  • Citadel Advisors reported no remaining Constellation Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • Citadel Advisors sold 152,848 Constellation Pharmaceuticals, Inc. shares in Q2 2021, an estimated $3.58M.
  • Citadel Advisors first reported a position in Constellation Pharmaceuticals, Inc. in Q4 2019 and held it in 6 quarters.
  • Citadel Advisors's Constellation Pharmaceuticals, Inc. position peaked at $9.48M in Q4 2020.
  • 153 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q2 2021.

Based on Citadel Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.